Skip to main content

Table 1

From: Methotrexate shows the same efficacy and safety in the real world in all subtypes of JIA as in the controlled trial

 

baseline

At 3 months

At 6 months

At 12 months

CHAQ-pain subscale

0.886

0.466

0.386

0.338

CHAQ-disability subscale

0.76

0.491

0.425

0.343

CHAQ-severity subsccale

0.398

0.248

0.184

0.207

Number of swollen joints

2.4

0.8

0.6

0.4

Number of tender joints

2.6

1.4

1.1

0.8

Number of joints with LROM

3.3

2.8

2.4

2.4

Physician global (VAS)

2.4

1.0

0.8

0.6

Elevated CRP

45.7%

14.3%

12.5%

42.9%

Elevated Sedimentation rate

43.8%

17.5%

21.1%

42.1%